MIRM - Mirum Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Foster City,
United States
Type: Equity
MIRM price evolution
MIRM
| (in millions $) | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $302.84 | $286.33 | $303.06 | $297.23 |
| Short term investments | $2.97 | $32.73 | ||
| Net receivables | $55 | $67.97 | $47.83 | $35.33 |
| Inventory | $21.61 | $19.59 | $22.25 | $8.51 |
| Total current assets | $389.46 | $384.82 | $388.58 | $383.52 |
| Long term investments | ||||
| Property, plant & equipment | $1.18 | $1.99 | $2.21 | $2.48 |
| Goodwill & intangible assets | $257.44 | $252.93 | $258.34 | $56.44 |
| Total noncurrent assets | $262.5 | $259.08 | $262.06 | $60.07 |
| Total investments | $2.97 | $32.73 | ||
| Total assets | $651.96 | $643.9 | $650.64 | $443.59 |
| Current liabilities | ||||
| Accounts payable | $15.98 | $7.42 | $7.37 | $14.45 |
| Deferred revenue | ||||
| Short long term debt | $0.36 | $1.1 | $1.08 | $1.06 |
| Total current liabilities | $105.91 | $85.68 | $74.66 | $58.2 |
| Long term debt | $307.16 | $306.42 | $306.89 | $306.76 |
| Total noncurrent liabilities | $311.45 | $310.89 | $306.9 | $306.77 |
| Total debt | $307.52 | $308.14 | $307.97 | $307.83 |
| Total liabilities | $417.36 | $392.72 | $381.56 | $364.98 |
| Shareholders' equity | ||||
| Retained earnings | -$581.52 | -$553.73 | -$520.58 | -$496.99 |
| Other shareholder equity | -$0.01 | $1.64 | -$1.46 | $0.08 |
| Total shareholder equity | $234.6 | $248.67 | $269.08 | $78.61 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $286.33 | $128 | $131.34 | $142.09 |
| Short term investments | $123.72 | $125.2 | $89.73 | |
| Net receivables | $67.97 | $23.99 | $3.27 | |
| Inventory | $19.59 | $5.57 | $1.51 | |
| Total current assets | $384.82 | $190.22 | $166.59 | $236.35 |
| Long term investments | $4.98 | |||
| Property, plant & equipment | $1.99 | $2.35 | $2.55 | $3.24 |
| Goodwill & intangible assets | $252.93 | $58.95 | $18.74 | |
| Total noncurrent assets | $259.08 | $162.68 | $128.06 | $4.51 |
| Total investments | $123.72 | $130.18 | $89.73 | |
| Total assets | $643.9 | $352.91 | $294.65 | $240.86 |
| Current liabilities | ||||
| Accounts payable | $7.42 | $8.69 | $9.17 | $3.15 |
| Deferred revenue | ||||
| Short long term debt | $1.1 | $0.93 | $0.71 | $0.64 |
| Total current liabilities | $85.68 | $64.73 | $42.6 | $18.46 |
| Long term debt | $306.42 | $141.61 | $131.83 | $50.28 |
| Total noncurrent liabilities | $310.89 | $146.14 | $131.84 | $50.31 |
| Total debt | $308.14 | $142.54 | $132.54 | $50.91 |
| Total liabilities | $392.72 | $210.87 | $174.44 | $68.77 |
| Shareholders' equity | ||||
| Retained earnings | -$553.73 | -$392.82 | -$257.16 | -$173.17 |
| Other shareholder equity | $1.64 | -$0.22 | -$0.04 | $0.08 |
| Total shareholder equity | $248.67 | $142.04 | $120.21 | $172.09 |
| (in millions $) | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $69.22 | $69.55 | $47.73 | $37.5 |
| Cost of revenue | $17.83 | $10.23 | $6.81 | |
| Gross Profit | $51.39 | $47.04 | $37.5 | $30.68 |
| Operating activities | ||||
| Research & development | $32.22 | $26.12 | $22.01 | |
| Selling, general & administrative | $45.64 | $36.53 | $32.95 | |
| Total operating expenses | $77.86 | $77.12 | $62.65 | $54.96 |
| Operating income | -$26.47 | -$25.15 | -$24.27 | |
| Income from continuing operations | ||||
| EBIT | -$21.08 | -$19.77 | -$70 | |
| Income tax expense | $0.62 | $0.23 | $0.25 | $0.32 |
| Interest expense | $3.58 | -$2.85 | $3.57 | $3.73 |
| Net income | ||||
| Net income | -$25.28 | -$33.15 | -$23.59 | -$74.04 |
| Income (for common shares) | -$25.28 | -$23.59 | -$74.04 | |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $186.37 | $77.06 | $19.14 | |
| Cost of revenue | $12.37 | $1.9 | ||
| Gross Profit | $141.84 | $64.69 | $17.23 | |
| Operating activities | ||||
| Research & development | $106.84 | $131.43 | $81.61 | |
| Selling, general & administrative | $89.07 | $59.22 | $22.69 | |
| Total operating expenses | $248.49 | $195.91 | $190.65 | $104.3 |
| Operating income | -$131.22 | -$173.41 | -$104.3 | |
| Income from continuing operations | ||||
| EBIT | -$126.09 | -$66.36 | -$102.93 | |
| Income tax expense | $0.99 | -$6.41 | $0.04 | $0.01 |
| Interest expense | -$4.19 | $15.98 | $17.59 | $0.34 |
| Net income | ||||
| Net income | -$160.91 | -$135.66 | -$83.99 | -$103.27 |
| Income (for common shares) | -$135.66 | -$83.99 | -$103.27 | |
| (in millions $) | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | -$25.28 | -$35.66 | -$23.59 | -$74.04 |
| Operating activities | ||||
| Depreciation | $5.66 | $5.64 | $2.85 | $1.48 |
| Business acquisitions & disposals | -$212.76 | |||
| Stock-based compensation | $11.45 | $9.72 | $8.38 | $8.36 |
| Total cash flows from operations | $15.21 | -$16.62 | -$18.22 | -$2.33 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.07 | ||
| Investments | $3 | $30 | $50.62 | |
| Total cash flows from investing | -$0.01 | -$2 | -$182.76 | $35.55 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.21 | $2.06 | $207.13 | $2.1 |
| Net borrowings | $112.61 | |||
| Total cash flows from financing | $1.21 | $1.78 | $207.13 | $114.71 |
| Effect of exchange rate | $0.11 | $0.11 | -$0.32 | -$0.11 |
| Change in cash and equivalents | $16.52 | -$16.73 | $5.83 | $147.81 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$163.41 | -$135.66 | -$83.99 | -$103.27 |
| Operating activities | ||||
| Depreciation | $11.45 | $3.68 | $0.97 | $0.62 |
| Business acquisitions & disposals | -$212.76 | |||
| Stock-based compensation | $35.02 | $27.01 | $23.09 | $12.55 |
| Total cash flows from operations | -$70.94 | -$120.14 | -$132.76 | -$89.08 |
| Investing activities | ||||
| Capital expenditures | -$0.11 | -$0.28 | $88.98 | -$0.23 |
| Investments | $125.67 | $7.98 | -$40.43 | $38.1 |
| Total cash flows from investing | -$107.2 | $7.7 | $48.55 | $37.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $227.15 | $114.64 | $9.01 | $131.87 |
| Net borrowings | $109.73 | -$5.55 | $64.45 | $49.58 |
| Total cash flows from financing | $336.6 | $109.09 | $73.47 | $181.29 |
| Effect of exchange rate | -$0.13 | $0.01 | -$0 | $0.03 |
| Change in cash and equivalents | $158.32 | -$3.34 | -$10.75 | $130.12 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $224.00M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$156.05M |
| Revenue Q/Q | 119.07% |
| Revenue Y/Y | 133.90% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -26.12% |
| ROE | -75.12% |
| Debt/Equity | 1.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.68 |
| Quick ratio | 3.47 |